The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.

ABSTRACT:

Background

The high costs of novel anticancer drugs have caused concern among healthcare stakeholders. To address the knowledge gap on the proportion of survival benefit with the related economic expenditure, we aimed to assess the correlation between the costs and value of innovative drugs targeted to specific tumours, before and after price negotiation policy implementation.

Methods

We identified new drugs for lung and breast cancer that entered the National Reimbursement Drug List (NRDL) through price negotiation from 2016 to 2023. Therapeutic value consisted of traditional clinical endpoints, like the percentage improvement of overall survival (ΔOS%) and progression-free survival (ΔPFS%), and the quantified gains of the American Society of Clinical Oncology Value Framewo

SUBMITTER: Bao Y 

PROVIDER: S-EPMC10629928 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature